Stephanie Hein

Title: Stephanie Hein: Innovator in RNA Vaccine Technology

Introduction

Stephanie Hein is a prominent inventor based in Rüsselsheim, Germany. She has made significant contributions to the field of vaccine development, particularly in the area of RNA technology. With a total of 3 patents to her name, her work is paving the way for innovative solutions in combating infectious diseases.

Latest Patents

One of her latest patents focuses on a coronavirus vaccine. This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Career Highlights

Stephanie Hein is currently associated with BioNTech SE, a leading biotechnology company known for its pioneering work in mRNA technology. Her role at BioNTech has allowed her to contribute to groundbreaking research and development in the field of vaccines.

Collaborations

She has collaborated with notable colleagues such as Ugur Sahin and Alptekin Güler, who are also recognized for their contributions to vaccine technology and innovation.

Conclusion

Stephanie Hein's work in RNA vaccine technology exemplifies the critical role of inventors in addressing global health challenges. Her innovative approaches and collaborations are instrumental in advancing the field of immunization.